We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED). Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design. Penile rigidity was monitored for 6 h using RigiScan. Level of sexual desire and side effects were reported with a questionnaire.
Introduction
Alpha-melanocyte-stimulating hormone (a-MSH) and adrenocorticotropin (ACTH), known as the melanocortins, have been implicated in the control of penile erection and sex behavior in animals. 1 ± 5 Five melanocortin receptor (MC-R) subtypes have been cloned, and reveal different functions based on localization. 6 MC1-R and MC2-R are the classical melanocytic and adrenocortical receptors in the skin and adrenal cortex respectively. 7, 8 MC3-R is principally present in the brain, with low levels of expression in the gut. 9 MC4-R is restricted to the nervous system; blockade of this receptor partially abolishes aMSH-induced erection in rats. 5 MC5-R has been localized in exocrine and endocrine glands including the reproductive tract of the rat. 6, 7 Melanocortins in¯uence important homeostatic behaviors mediated by the hypothalamus. Melanocortinergic neurons exert a tonic inhibition of feeding behavior. Chronic disruption of this inhibitory signal by the agouti peptide is a likely explanation of the agouti obesity syndrome in mice. 10 The agouti peptide is an MCR-4 antagonist.
Melanocortins regulate sexual behavior including penile erection, sexual motivation, and, in the female rat the secretion of sexual attractants from the preputial gland. 6 a-MSH and ACTH are believed to act downstream from dopamine and oxytocin in the hypothalamic proerectile centers adjacent to the third ventricle. 2 MC5-R expression among peripheral tissues provides a functional coherence between central and peripheral control of sex behavior. 6 A number of melanocortin agonists have been synthesized to enhance skin pigmentation. 11 Melanotan I, a linear peptide analog of a-MSH, causes tanning. 12 Melanotan II, a cyclic non-selective melanocortin receptor agonist, initiates erections in rats, dogs, and humans. 13, 14 We report our experience with Melanotan II in human subjects with erectile dysfunction (ED). 13, 15 Materials and methods
Subjects
Men aged 18 ± 75 y with a chief complaint of ED were enrolled in two studies. 13, 15 In Study 1 men with no organic etiologies and normal nocturnal penile tumescence ( b 10 min of tip rigidity b 70%) were enrolled and designated as having psychogenic erectile dysfunction. Men with ED and major organic risk factors were enrolled in Study 2. The pertinent characteristics of the study populations are listed in Table 1 . Erectile dysfunction was de®ned as the persistent inability to obtain and maintain an erection suf®cient for sexual satisfaction. 16 The Human Subjects Committee of the University of Arizona approved the studies, and written informed consent was obtained on all subjects.
Peptide chemistry:
Melanotan II is a synthetic cyclic heptapeptide, AcNle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH 2 , which contains the 4 ± 10 melanocortin receptor binding region common to ACTH and MSH, but with a lactam bridge and four amino acid substitutions ( Figure 1 ).
Drug synthesis and puri®cation were carried out as previously described. 17 
Experimental design
A double blind, placebo-controlled crossover design was used. Melanotan II (0.025 ± 0.157 mgakg) and vehicle were each administered by the investigator twice by subcutaneous injection for a total of four injections; study drug doses were separated by at least 48 h. The order of administration was randomly assigned.
Penile erection was measured with real-time RigiScan monitoring in the home situation ( Figure  2 ). Subjects were instructed to avoid erotic stimuli and to remain awake for the 6 -h session. Subjects recorded the number and duration of erectile events. In Study 2, sexual desire was scored from 1 to 5 using a modi®cation of IIEF question 12. 18 Side effects (none, mild, moderate, or severe) were recorded for: nausea; yawning or stretching; facial ushing; decreased appetite; increased appetite; and drowsiness. Subjects denoted onset of symptoms, duration, and measures taken to relieve them. Antiemetics were not prescribed.
Statistical analysis
Mean values of RigiScan parameters after Melanotan II and placebo were compared with the one-tailed 
Results
Twenty subjects aged 22 ± 67 y (mean 51.6 y) were enrolled and completed the studies between July 1995 and December 1998. 13, 15 Thirty-nine total injections of Melanotan II were given and 41 of placebo (one subject received three placebo injections and one of Melanotan II due to erroneous administration of vials discovered after completion of the study). No patient withdrew because of side effects.
Of 20 subjects, 17 reported subjectively apparent erection on at least one of two injections of Melanotan II. Overall, erectile activity was reported with 27a39 (69%) Melanotan II injections and 1a41 a RigiScan data based on 16 injections due to loss of data from three injections in three subjects, one of whom who reported no erection and two of whom had signi®cant erections (60 and 90 min duration, 9a10 rigidity by visual analog scale). Human studies with melanocortin receptor agonists H Wessells et al placebo injections (P`0.01). Twelve subjects responded to each Melanotan II injection, ®ve responded to only one of two doses, and three men had no erectile activity with Melanotan II. RigiScan results showed statistically signi®cant differences in erectile activity between Melanotan II and placebo (Table 2 ). Latency to ®rst erection ranged from 15 to 270 min (mean 115). Duration of rigidity between 80 and 100% ranged from 0 to 254 min on Melanotan II (mean 41.0). Tip Rigidity Activity Units were 78.4 and 58.6 in psychogenic and organic ED patients respectively (P 0.49). The subject with 254 min of rigidity had two episodes of complete detumescence dividing the erections (see Figure 3) , and no subject reported a painful erection.
Heightened sexual desire was reported in Study 2 after 13a19 (68%) doses of Melanotan II vs 4a21 (19%) of placebo (P 0.0034). Table 3 shows the individual responses. Of the 10 subjects reporting a moderate or high level of desire, all but one developed a penile erection. Mean level of sexual desire (scale 1 ± 5) was 2.47 after Melanotan II vs 1.24 on placebo (P`0.001).
Nausea and stretchingayawning occurred signi®-cantly more frequently with Melanotan II than placebo (Table 4 ), but no serious or unexpected adverse events occurred. Nausea was reported with 15a39 (38%) injections of Melanotan II, including severe nausea in six cases (15.3%, P`0.05 vs placebo). One subject vomited in association with an episode of severe nausea. Four of 31 (12.9%) injections of 0.025 mgakg Melanotan II led to severe nausea. No subject experienced severe nausea with both administrations of Melanotan II, and symptoms were reduced, in eight of 11 instances, on second dosage of the drug.
Discussion
Melanotan II, a non-speci®c MCR agonist, initiates erections in men with organic and psychogenic erectile dysfunction. Seventeen of 20 subjects reported penile erection, although not with each administration. The majority of erections induced by Melanotan would be considered suf®cient for sexual intercourse: tip rigidity time b 80% averaged 41 min. The magnitude and duration of erectile activity was greater in the psychogenic ED patients than organic ED patients, although this difference was not statistically signi®cant. The nature and severity of the erectile dysfunction was not completely characterized in these studies, making comparison of results between the two groups dif®cult. We found no signi®cant correlation between duration of prestudy NPT and response to Melanotan II, although subjects only underwent one night of NPT testing.
The mean erectile latency time of 112.6 min for Melanotan II is long for a clinically useful drug. However, the addition of erotic stimulation may lead to responses that are more rapid. It is possible that the RigiScan device, through intermittent constriction of the penis, provides some sexual stimulation. Melanotan II in all likelihood must cross the blood brain barrier for its activity, which may explain the prolonged time to peak effect. Modi®cation of drug delivery may enhance acceptability for clinical use. The time at which nausea was ®rst reported, on average 168 min after injection, suggests that the gastrointestinal side effects are centrally mediated as well. The exact locus of action of Melanotan II remains unknown, but strong circumstantial evidence points to a central mechanism. Intracerebroventricular administration of Melanotan II in rats leads to erection and yawning, and no change in intracavernous pressure was observed after intracavernous injection (unpublished data). Melanotan I, a non-cyclic MCR agonist that does not cross the blood brain barrier, has no erectogenic activity. Further animal studies using selective melanocortin antagonists and agonists and receptor localization will be necessary to identify its pharmacological mechanism.
We could not differentiate Melanotan II responders from non-responders based on NPT criteria, testosterone levels, or etiology of ED. Our combined data make it unlikely that Melanotan II could be used as a diagnostic tool to differentiate organic and psychogenic etiologies. Differences were noted in the onset and duration of erectile activity between psychogenic and organic subjects. In the absence of pharmacokinetic data on these subjects, any explanation of these differences remains speculative. It is intriguing to consider, however, that psychogenic inhibition of arousal may contribute to a delayed onset of erectile activity, whereas organic etiologies reduce the total duration and magnitude of response.
The increased sexual desire scores after Melanotan II may re¯ect the wording of IIEF question 12, which describes sexual desire as`wanting to have a sexual experience, thinking about having sex, or feeling frustrated due to lack of sex'. 18 These responses certainly would not be surprising in men with ED who develop penile erections and cannot engage in sexual activity. Investigation of this ®nding in subsequent home use studies would be essential before further commercialization of the drug.
The safety pro®le of Melanotan II is acceptable: no serious adverse event occurred, and only one subject requested antiemetic therapy. Nausea and stretchingayawning were reported more commonly after Melanotan II than placebo in both studies. While 38% of subjects reported nausea, the incidence of severe nausea at our preferred dose of 0.025 mgakg was 12.9%. We noted a reduction in the incidence and severity of nausea with the second administration of the drug, suggesting a ®rst dose effect. Only one subject reported skin pigmentation, and a cumulative dose of 0.1 mgakg is necessary for skin tanning. 14 Yawning occurred with a signi®cantly higher frequency after Melanotan II than placebo. We believe that this phenomenon is analogous to the stretchingayawning syndrome observed in rats. The stretchingayawning syndrome, an ancestral vestige that subserves arousal, is mediated by hypothalamic centers in proximity to the paraventricular nucleus. 2 Melanotan II may eventually prove to be bene®cial for patients with ED. However, the incidence of severe nausea and prolonged latency time raise questions about the potential clinical applications of the drug. 15 The pharmacokinetics and lowest effective dose of Melanotan II must be determined in order to reduce side effects without reduction in erectogenic activity.
Conclusions
Melanotan II, a non-selective MCR agonist, initiated penile erections in 69% of administrations in men with psychogenic and organic ED. Mean duration of real-time RigiScan tip rigidity b 80% was 41 min; the time to onset (mean 112 min) was longer for men with psychogenic ED compared to those with organic ED, although the former group had more sustained rigidity and a higher overall response rate.
Side effects of nausea and yawningastretching occurred more frequently with Melanotan II than with placebo, including a 15.3% incidence of severe nausea. The observation of increased sexual desire with Melanotan II is novel and warrants further investigation. Further studies to localize the site of action and receptor subtype mediating the action of Melanotan II may allow development of targeted receptor-speci®c melanocortin therapy for ED.
